Abstract
(May 14, 2020)
The epidemiological data up to 12th May 2020 for India and its 24 states has been used to predict COVID-19 outbreak within classical SIR (Susceptible-Infected-Recovered) model. The basic reproduction number R0 of India is calculated to be 1.15, whereas for various states it ranges from 1.03 in Uttarakhand to 7.92 in Bihar. The statistical parameters for most of the states indicates the high significance of the predicted results. It is estimated that the epidemic curve flattening in India will start from the first week of July and epidemic may end in the third week of October with final epidemic size ∼1,75,000. The epidemic in Kerala is in final phase and is expected to end by first week of June. Among Indian states, Maharashtra is severely affected where the ending phase of epidemic may occur in the second week of September with epidemic size of ∼55,000. The model indicates that the fast growth of infection in Punjab is from 27th April 2020 to 2nd June 2020, thereafter, curve flattening will start and the epidemic is expected to finished by the first week of July with the estimated number of ∼3300 infected people. The epidemic size of COVID-19 outbreak in Delhi, West Bengal, Gujrat, Tamil Nadu and Odisha can reach as large as 24,000, 18,000, 16,000, 13,000 and 11,000, respectively, however, these estimations may be invalid if large fluctuation of data occurs in coming days.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No Funding for this research
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
No specific data reported.
